London
· Delayed Price · Currency is GBP · Price in USD UroGen Pharma Company Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H.
to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma.
UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Country | Israel |
| Founded | 2004 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 201 |
| CEO | Elizabeth Barrett |
Contact Details
Address: 400 Alexander Park Drive Princeton, 08540 United States | |
| Phone | 646 768 9780 |
| Website | urogen.com |
Stock Details
| Ticker Symbol | 0XOD |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Elizabeth Barrett | Chief Executive Officer |
| Christopher Degnan | Chief Financial Officer |
| Vincent Perrone | Head of Investor Relations |